The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT

Blood

Volumn 106, Issue 13, 2005, Pages 4322-4329

  David, Ebenezer ^a   Sun, Shi Yong ^a   Waller, Edmund K ^a   Chen, Jing ^a   Khuri, Fadlo R ^a   Lonial, Sagar ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; LONAFARNIB; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME DEGRADATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 28844500739     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2584     Document Type: Article

References (47)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
3. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
4. Richardson P, Schlossman R, Hideshima T, et al. A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM) [abstract]. American Society of Hematology. Orlando, FL; 2001:775a.
5. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
6. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374-14379.
7. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.
8. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
9. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol. 2001;38:16-23.
10. Ochiai N, Uchida R, Fuchida S, et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood. 2003;102:3349-3353.
11. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther. 2004;3:179-186.
12. Shi Y, Gera J, Hsu JH, Van Ness B, Lichtenstein A. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol Cancer Ther. 2003;2:563-572.
13. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004;103:3271-3277.
14. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159:2212-2221.
15. Gado K, Domjan G, Hegyesi H, Falus A. Role of interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int. 2000;24:195-209.
16. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991;77:587-593.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
18. Eskens FA, Awada A, Cutler DL, et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 2001;19:1167-1175.
19. Anderson KC. Moving disease biology from the lab to the clinic. Cancer. 2003;97:796-801.
20. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
21. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003;10:361-369.
22. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib vs dexamethasone in relapsed multiple myeloma: a phase III randomized study. American Society of Clinical Oncology. New Orleans, LA; 2004:558.
23. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058-3065.
24. Zangari M, Barlogie B, Hollmig K, et al. Marked activity of velcade + thalidomide in advanced and refractory multiple myeloma [abstract]. American Society of Hematology. San Diego, CA: 2004:413a.
25. Yang HH, Vescio R, Schenkein D, Berenson JR. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, Velcadetrade mark) and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymph. 2003;4:119-122.
26. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
27. Heffner LT Jr, Lonial S. Breakthroughs in the management of multiple myeloma. Drugs. 2003;63:1621-1636.
28. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003;101:3126-3135.
29. Hirano T. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int J Cell Cloning. 1991;9:166-184.
30. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003;102:3880-3889.
31. Winquist E, Moore MJ, Chi KN, et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol. 2005;23:143-149.
32. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol. 2001;13:470-476.
33. Khuri FR, Glisson BS, Kim ES, et al. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004;10:2968-2976.
34. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871-1877.
35. Blumenschein G, Ludwig C, Thomas G, et al. A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) [suppl 2]. Lung Cancer. 2005;49: S30.
36. Brodsky AL. Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. Blood. 2003;101:2070.
37. Nakajima A, Tauchi T, Sumi M, Bishop WR, Ohyashiki K. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther. 2003;2:219-224.
38. Le Gouill S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia. 2002;16:1664-1667.
39. Marcus AI, Zhou J, O'Brate A, et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. 2005;65:3883-3893.
40. Sharma S, Kemeny N, Kelsen DP, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002;13:1067-1071.
41. Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer. 2004;4:56.
42. Sun SY, Zhou Z, Wang R, Fu H, Khuri FR. The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. Cancer Biol Ther. 2004;3:1092-1098.
43. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res. 2004;64:8688-8693.
44. Elam C, Hesson L, Vos MD, et al. RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res. 2005;65:3117-3125.
45. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
46. Harousseau L-L, Stone R, Thomas X, et al. Interim results from a phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia [abstract]. Proc Am Soc Clin Oncol. 2002;21:265a. Abstract no. 1056.
47. Lancet JE, Gojo I, Gotlib J, et al. Tipifarnib (Zarnestra) in previously untreated poor-risk AML and MDS: interim results of a phase 2 trial [abstract]. Blood. 2003;102:176a. Abstract no. 613.